Probiotic Infection Risk in Very Preterm Infants

Can probiotics cause infections in premature babies?

Probiotics contain live microorganisms, so there is a biologically plausible risk that an administered organism could cross an immature intestinal barrier or contaminate a central venous catheter. Very preterm infants may have fragile intestinal tissue, underdeveloped immune responses and serious underlying illness, all of which can increase the consequences of bloodstream infection.

The newly reported cohort included more than 100,000 very preterm infants and found 11 probiotic-associated invasive infections. That low absolute count is reassuring, but retrospective research can miss cases if microbiological testing, organism identification or documentation is incomplete. Clinicians must therefore interpret the result alongside each infant's condition and the safety record of the specific product.

Do probiotics prevent serious intestinal disease in preterm infants?

Necrotizing enterocolitis is a potentially life-threatening intestinal disease that disproportionately affects premature infants. Systematic reviews of randomized trials have reported that certain probiotic regimens can reduce severe necrotizing enterocolitis and may improve other outcomes, but the trials have used different organisms, combinations, doses and manufacturing standards.

This variability matters because probiotics are not a single interchangeable treatment. Evidence supporting one studied strain or combination does not establish that every commercial product is effective. The American Academy of Pediatrics has cautioned against routine universal administration to preterm infants, particularly those with extremely low birth weight, because pharmaceutical-grade products are not consistently available and long-term safety evidence remains limited.

How should neonatal units evaluate probiotic safety?

Safety assessment should include confirmation of the organism and dose, testing for contamination, reliable storage conditions and the ability to trace individual product lots. Staff also need procedures that reduce accidental spread to intravenous lines, equipment or other infants when opening and administering products containing live microorganisms.

The U.S. Food and Drug Administration has warned that hospitalized preterm infants given probiotics may face a risk of invasive, potentially fatal infection. Decisions should therefore involve neonatologists, pharmacists, microbiology laboratories, infection-prevention teams and parents. The new cohort helps quantify a rare harm, but it should support careful risk-benefit evaluation rather than unsupervised probiotic use.